Cancer

Peru: Better Cancer Survival Rates Than Europe or the US

Despite Peru’s sometimes-sluggish development when it comes to healthcare, the progression of cancer prevention and control in recent decades is tremendous. This is particularly important as the number of cancer cases…

NHS approves ‘game-changing’ cell therapy for children with cancer

Novartis receives NHS approval for their CAR T-cell therapy to treat leukaemia in children, 10 days after…

Celltrion Wins Big Deal for Breast Cancer Biosimilar in French Hospitals

Celltrion Healthcare, the marketing arm of the biopharmaceutical company Celltrion won a huge deal in France last…

Turkey: The Future of Cancer Care Uncertain

Turkey has one of the most revered Social Security Systems in the world, providing its citizens with…

In Conversation

Kshitij Panse, director of Servier Malaysia discusses the company’s planned move into oncology, as well as their strategies to provide an all-round improved patient experience, through education, screening, and e-health. Oncology is the future, and we want to introduce the products in Servier’s pipeline to Malaysia as and when they become available Before taking over the Malaysian affiliate you…

Korean Research Team Develops Nanoparticle for Cancer Treatment

A Korean research team at Ulsan National Institute of Science and Technology (UNIST) have developed a cunning…

Euratom: Where Are We Now?

Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will &…

Countering NCDs in Algeria

Long considered maladies of affluent urban populations in mature Western economies, non communicable diseases…

Korea’s Government-Funded Venture into Oncology

National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to…

Dying to Survive

This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special…

Novartis: EU approve gene-modifying cancer therapy

This week Novartis received approval from the European Commission (EC) for Kymriah, their chimeric antigen…